|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Southwest Oncology Group |
|---|---|
| Collaborators: |
National Cancer Institute (NCI) Eastern Cooperative Oncology Group |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00003292 |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.
| Condition | Intervention | Phase |
|---|---|---|
|
Chondrosarcoma Adult Fibrosarcoma Adult Leiomyosarcoma Adult Rhabdomyosarcoma Adult Malignant Meningioma Adult Brain Malignant Hemangiopericytoma |
Drug: ifosfamide Procedure: chemotherapy |
Phase II |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors |
OBJECTIVES:
OUTLINE: All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course. Patients are evaluated for response/progression after every 2 courses. Patients with stable disease receive up to 8 courses of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year, then every 6 months thereafter.
PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Contacts and Locations
Show 70 Study Locations| Study Chair: | Leslie McAllister, MD | Neurological Clinic |
| Study Chair: | Lynn G. Feun, MD | University of Miami Sylvester Comprehensive Cancer Center |
More Information
| ClinicalTrials.gov Identifier: | NCT00003292 History of Changes |
| Other Study ID Numbers: | CDR0000066225, SWOG-S9624, E-S9624, NABTT-S9624 |
| Study First Received: | November 1, 1999 |
| Last Updated: | January 11, 2007 |
| Health Authority: | United States: Federal Government |
|
Chondrosarcoma Fibrosarcoma Hemangiopericytoma Leiomyosarcoma Meningeal Neoplasms Meningioma Rhabdomyosarcoma Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Sarcoma Neoplasms, Fibrous Tissue Neoplasms, Vascular Tissue Neoplasms, Muscle Tissue |
Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Nervous System Diseases Neoplasms, Nerve Tissue Myosarcoma Ifosfamide Isophosphamide mustard Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents Therapeutic Uses |